may reduce ART receipt and medication adherence in this population [2] [3] [4] . We examined whether retention in care, use of ART, and HIV suppression differed between transgender and nontransgender PLWH.
We performed a retrospective cohort study of HIV-infected adults (≥18 years) initiating care at 13 HIV clinics in the HIV Research Network (HIVRN) between 2001 and 2011. Clinics are located in the Northeastern (n = 6), Midwestern a Age, race/ethnicity, HIV risk factor, and insurance were compared using the χ 2 test of independence. CD4 count and HIV load were compared using the KruskalWallis test due to their nonnormal distribution. b P < .01 when comparing nontransgender men to transgender persons. c P < .01 when comparing nontransgender women to transgender persons. d Patients who had IDU in combination with another risk factor were categorized as injection drug users.
e Calculated for 106 440 patient years eligible for the retention in care analysis. Patients newly enrolled in care during the last 6 months of the year or who died in the first 6 months of the year were excluded. f Calculated for 72 728 patient-years eligible for the HIV suppression analysis in which ART was prescribed for >6 months.
(n = 1), Southern (n = 3), and Western (n = 3) regions of the United States. Data from patients' medical records were abstracted, quality assured, and assembled into a uniform database [5] . All clinics had institutional review board approval.
Gender was self-identified and categorized as nontransgender men, nontransgender women, and transgender. Dichotomous outcomes were retention in care (≥2 primary HIV visits ≥90 days apart), use of ART, and HIV suppression (median HIV RNA <400 copies/mL) in each calendar year. Multivariate logistic regression, adjusted for age, race/ethnicity, HIV risk, insurance, CD4 count, calendar year, and site of care, examined associations between gender and each outcome. Because patients contributed data in multiple years, we used generalized estimating equations, clustered on patient, with exchangeable working correlation and robust standard errors to deal with the correlation across years for individual patients. Two-sided testing was used, with a P value of <.05 considered significant.
A total of 36 845 PLWH, of whom 285 self-identified as transgender, received care at HIVRN clinics between 2001 and 2011 (Table 1) . Transgender patients were more likely to be young and Hispanic, and to be men who have sex with men as their HIV risk behavior compared to nontransgender PLWH. Transgender persons were retained in care, received ART, and achieved HIV suppression in 80%, 76%, and 68% of patient-years, respectively. Corresponding results were 81%, 77%, and 69% for nontransgender men, and 81%, 73%, and 63% for nontransgender women.
In Compared to prior studies, which document low ART coverage and suboptimal adherence to HIV treatment in transgender PLWH, these results reflect improvements in health equity for HIVinfected transgender individuals [3, 6] . Advances in HIV therapy, including new antiretroviral drugs with simplified dosing and greater tolerability, and treatment guidelines may explain these findings [7, 8] . This study is limited by its retrospective nature, small sample of transgender individuals, and focus on patients engaged in care. While our findings may not generalize to all transgender PLWH, they suggest that when engaged in care transgender PLWH have similar outcomes as nontransgender men and women.
Notes

